Literature DB >> 15932767

Self-administration of cannabinoids by experimental animals and human marijuana smokers.

Zuzana Justinova1, Steven R Goldberg, Stephen J Heishman, Gianluigi Tanda.   

Abstract

Drug self-administration behavior has been one of the most direct and productive approaches for studying the reinforcing effects of psychoactive drugs, which are critical in determining their abuse potential. Cannabinoids, which are usually abused by humans in the form of marijuana, have become the most frequently abused illicit class of drugs in the United States. The early elucidation of the structure and stereochemistry of delta-9-tetrahydrocannabinol (THC) in 1964, which is now recognized as the principal psychoactive ingredient in marijuana, activated cannabinoid research worldwide. This review examines advances in research on cannabinoid self-administration behavior by humans and laboratory animals. There have been numerous laboratory demonstrations of the reinforcing effects of cannabinoids in human subjects, but reliable self-administration of cannabinoids by laboratory animals has only recently been demonstrated. It has now been shown that strong and persistent self-administration behavior can be maintained in experimentally and drug-naïve squirrel monkeys by doses of THC comparable to those in marijuana smoke inhaled by humans. Furthermore, reinforcing effects of some synthetic CB1 cannabinoid agonists have been recently reported using intravenous and intracerebroventricular self-administration procedures in rats and mice. These findings support previous conclusions that THC has a pronounced abuse liability comparable to other drugs of abuse under certain experimental conditions. Self-administration of THC by squirrel monkeys provides the most reliable animal model for human marijuana abuse available to date. This animal model now makes it possible to study the relative abuse liability of other natural and synthetic cannabinoids and to preclinically assess new therapeutic strategies for the treatment or prevention of marijuana abuse in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15932767      PMCID: PMC2679508          DOI: 10.1016/j.pbb.2005.01.026

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  153 in total

1.  Methohexital and cocaine self-administration under fixed-ratio and second-order schedules.

Authors:  D J Spear; C Muntaner; S R Goldberg; J L Katz
Journal:  Pharmacol Biochem Behav       Date:  1991-02       Impact factor: 3.533

2.  Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination.

Authors:  J L Wiley; B R Martin
Journal:  Pharmacol Biochem Behav       Date:  1999-11       Impact factor: 3.533

3.  A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.

Authors:  E Valjent; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

4.  The effects of orally administered delta 9-tetrahydrocannabinol in man on mood and performance measures: a dose-response study.

Authors:  G B Chesher; K D Bird; D M Jackson; A Perrignon; G A Starmer
Journal:  Pharmacol Biochem Behav       Date:  1990-04       Impact factor: 3.533

5.  Mesolimbic dopaminergic decline after cannabinoid withdrawal.

Authors:  M Diana; M Melis; A L Muntoni; G L Gessa
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

6.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

7.  Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH)

Authors:  M A Huestis; J E Henningfield; E J Cone
Journal:  J Anal Toxicol       Date:  1992 Sep-Oct       Impact factor: 3.367

8.  Comparison of effects of marihuana cigarettes to three different potencies.

Authors:  M Perez-Reyes; S Di Guiseppi; K H Davis; V H Schindler; C E Cook
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

9.  A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro.

Authors:  Benjamin J Whalley; Jonathan D Wilkinson; Elizabeth M Williamson; Andrew Constanti
Journal:  Neurosci Lett       Date:  2004-07-15       Impact factor: 3.046

10.  Preference for high- versus low-potency marijuana.

Authors:  L D Chait; K A Burke
Journal:  Pharmacol Biochem Behav       Date:  1994-11       Impact factor: 3.533

View more
  48 in total

Review 1.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

3.  Voluntary oral consumption of Δ9-tetrahydrocannabinol by adolescent rats impairs reward-predictive cue behaviors in adulthood.

Authors:  Lauren C Kruse; Jessica K Cao; Katie Viray; Nephi Stella; Jeremy J Clark
Journal:  Neuropsychopharmacology       Date:  2019-04-10       Impact factor: 7.853

4.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

Review 5.  The endocannabinoid system in brain reward processes.

Authors:  M Solinas; S R Goldberg; D Piomelli
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

6.  A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.

Authors:  Sevil Yasar; József Gaál; Leigh V Panlilio; Zuzana Justinova; Szecsö V Molnár; Godfrey H Redhi; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

Review 7.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

8.  Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Authors:  Zuzana Justinova; Regina A Mangieri; Marco Bortolato; Svetlana I Chefer; Alexey G Mukhin; Jason R Clapper; Alvin R King; Godfrey H Redhi; Sevil Yasar; Daniele Piomelli; Steven R Goldberg
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

Review 9.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

10.  Repeated Δ9-tetrahydrocannabinol exposure in adolescent monkeys: persistent effects selective for spatial working memory.

Authors:  Christopher D Verrico; Hong Gu; Melanie L Peterson; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2014-04       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.